cardiovascular imaging News
-
Thoma Bravo Completes Strategic Growth Investment in Circle Cardiovascular Imaging
Thoma Bravo, a leading software investment firm, today announced the completion of its strategic growth investment in Circle Cardiovascular Imaging Inc. ("Circle CVI"), the global leader in cardiovascular imaging solutions. Circle CVI is the leading provider of AI-based cardiac imaging and reporting solutions, including cardiac MRI ("CMR") and cardiac computerized tomography ("CT") imaging ...
-
IFEMA will host the ESC Congress in 2025
In 2025, IFEMA will host the annual congress of the European Society of Cardiology, ESC Congress 2025, the largest congress in the world in this speciality, the holding of which will give Madrid a strong boost, confirming the city as a preferred international destination for business tourism. This has been confirmed by the European Society of Cardiology, which annually celebrates its congress, ...
-
IFEMA MADRID will held Heart Failure Congress in 2022
This announcement comes a few months after the ESC selected the Institution as host venue for its global congress for 2025, confirming the attractiveness of IFEMA MADRID and Madrid as a host city for large high-level medical congresses. The HFA comprises more than 10,000 members, and past Heart Failure congresses have hosted 5,500 to 6,000 delegates at their in-person editions. The ...
-
Circle Cardiovascular Imaging Announces Strategic Growth Investment from Thoma Bravo
Circle Cardiovascular Imaging Inc. ("Circle CVI"), the global leader in cardiovascular imaging solutions, today announced a strategic growth investment from Thoma Bravo, a leading software investment firm. Thoma Bravo's partnership is expected to drive future investment in product innovation, extend Circle CVI's market leadership position and fuel future growth. Financial terms of the transaction ...
-
GE Healthcare in collaboration with Nex Cubed select six digital health start-ups for inaugural Edison Accelerator in Canada
Six digital health start-ups from five countries have officially become the first cohort of the Edison Accelerator in Canada – a program designed by GE Healthcare and delivered in collaboration with Nex Cubed to accelerate, validate, and scale innovative solutions that address important challenges in the healthcare sector. The companies all focus on applying Artificial Intelligence (AI) to ...
-
Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer
BOSTON – July 26, 2022 – Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development ...
By Elucid
-
Medis Strain algorithms integrated in FetalHQ
MedisStrain Algorithms Integrated infetalHQ Our Strain algorithms are integrated in thefetalHQ imaging tool which is available on Voluson™ Expert 22 from GE Healthcare.fetalHQ allows users to make an easy and comprehensive evaluation of the size, shape, and contractility of the fetal heart to make more informed decisions about maternal/ fetal well-being and delivery planning using ...
-
Study Demonstrates Elucid’s Ability to Estimate RNA Expression from Non-Invasive Cardiovascular Imaging
Early detection of high risk plaque phenotypes holds the promise to prevent myocardial infarction and ischemic stroke by enabling personalized therapeutics BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, and researchers at the Karolinska Institutet (Stockholm, Sweden), led by Dr. Ulf Hedin, announced ...
By Elucid
-
CardioWise Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Receives Patents from Both the United States and the European Union
CardioWise, Inc., is pleased to announce two significant patents protecting its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). The European Union Patent Number 12839978.9 was awarded on February 2, 2019, followed closely by the U.S. Patent on June 7, 2019 (patent application number 14/350,991). Both patents are entitled “Methods for Evaluating ...
-
Studies suggest Elucid’s AI software helps to objectively quantify key drivers of stroke and heart attack from computed tomography angiography (CTA)
Computed tomography angiography (CTA) has been increasingly used in the diagnosis of vascular disease and its a modality that offers many potential clinical benefits. The question is, how to actualize that benefit and get the most our of the modality. Elucid has developed an artificial intelligence software that might just answer that question. How AI Can Improve CTA Analysis ...
By Elucid
-
Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies at the virtual Society of Cardiovascular Computed Tomography (SCCT) 16th Annual Scientific Meeting. The studies ...
By Elucid
-
FFR-SEARCH Shows Clear Trend Towards Major Adverse Cardiac Events with Lower FFR
Dr. Roberto Diletti from The Erasmus Center in Rotterdam, Netherlands, presented the results of the two-year follow-up analysis of the FFR-SEARCH observational registry during the EuroPCR conference in Paris. The analysis evaluated the outcomes of patients and prognostic value of post-percutaneous coronary intervention (post-PCI) FFR assessment, indicating patients with a lower FFR post-PCI ...
-
Nanox Announces Issuance of American Medical Association New Category III CPT® Code for Its Coronary Artery Calcium Population Health Solution
NEVE ILAN, Israel--(BUSINESS WIRE)--Jan. 11, 2022-- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and its deep-learning medical imaging analytics subsidiary, Nanox.AI, today announced that the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT) code for quantitative CT tissue ...
-
Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared to previous therapy 40% of patients experienced exceptional responses lasting at least three ...
By Exscientia
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you